文献速递妇科

贝伐珠单抗与二次肿瘤细胞减灭术对铂敏感复发性卵巢透明细胞癌生存结局的影响:韩国多中心研究

Impact of bevacizumab and secondary cytoreductive surgery on survival outcomes in platinum-sensitive relapsed ovarian clear cell carcinoma: A multicenter study in Korea.
PubMed 文献 · Gynecol Oncol · 2022-07-19

该多中心研究纳入2007年7月至2021年6月在五家机构接受二线治疗的铂敏感复发性卵巢透明细胞癌患者138例,比较二线化疗中使用贝伐珠单抗及二次肿瘤细胞减灭术的生存结局。贝伐珠单抗组无进展生存期和总生存期优于非贝伐珠单抗组,二次手术组无进展生存期和总生存期也显著优于未手术组。作者认为贝伐珠单抗和二次肿瘤细胞减灭术可能改善铂敏感复发性卵巢透明细胞癌患者的无进展生存期和总生存期,需进一步前瞻性研究。

要点

  • 贝伐珠单抗组中位无进展生存期15.4个月 vs 非贝伐珠单抗组7.5个月(P=0.042)。
  • 二次肿瘤细胞减灭术组中位无进展生存期33.7个月 vs 未手术组7.2个月(P<0.001)。
  • 贝伐珠单抗和二次肿瘤细胞减灭术可能改善铂敏感复发性卵巢透明细胞癌的生存结局。

核心结论

  • 二线化疗中使用贝伐珠单抗及二次肿瘤细胞减灭术可能改善铂敏感复发性卵巢透明细胞癌患者的无进展生存期和总生存期,需进一步前瞻性研究。

研究设计与样本

  • 多中心研究,纳入2007年7月至2021年6月在五家机构接受二线治疗的铂敏感复发性卵巢透明细胞癌患者138例。
  • 按二线化疗中是否使用贝伐珠单抗(贝伐珠单抗组36例,非贝伐珠单抗组102例)及是否行二次肿瘤细胞减灭术(手术组42例,未手术组96例)比较患者特征和生存结局。

主要发现

  • 贝伐珠单抗组与非贝伐珠单抗组初始FIGO分期和二次肿瘤细胞减灭术比例相似。
  • 贝伐珠单抗组中位无进展生存期15.4个月 vs 非贝伐珠单抗组7.5个月(P=0.042),总生存期也优于非贝伐珠单抗组(P=0.043)。
  • 多因素分析中,贝伐珠单抗是无进展生存期的独立预后因素(校正风险比[aHR] 0.571;95%置信区间[CI] 0.354-0.921;P=0.022)和总生存期的独立预后因素(aHR 0.435;95%CI 0.195-0.970;P=0.042)。
  • 二次肿瘤细胞减灭术组较未手术组诊断时早期疾病更常见(P=0.009)、复发时多部位转移更少见(P<0.001);二次肿瘤细胞减灭术组中位无进展生存期33.7个月 vs 未手术组7.2个月(P<0.001),总生存期也显著更优(P<0.001)。
  • 二次肿瘤细胞减灭术与无进展生存期显著改善相关(aHR 0.297;95%CI 0.183-0.481;P<0.001)和总生存期显著改善相关(aHR 0.276;95%CI 0.133-0.576;P=0.001);在行二次肿瘤细胞减灭术的患者中,贝伐珠单抗组与非贝伐珠单抗组无进展生存期和总生存期相似,而在未手术患者中贝伐珠单抗组无进展生存期和总生存期改善。

临床怎么用

  • 作者认为,二线化疗中使用贝伐珠单抗及二次肿瘤细胞减灭术可能改善铂敏感复发性卵巢透明细胞癌患者的无进展生存期和总生存期。

局限性

  • 原文结论指出需进一步前瞻性研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: This study investigated survival outcomes for platinum-sensitive relapsed ovarian clear cell carcinoma (OCCC) by treatment method. METHODS: OCCC patients with platinum-sensitive recurrence that received secondary treatment at five institutions between July 2007 and June 2021 were included. Patient characteristics and survival outcomes were compared according to the use of bevacizumab (BEV) during second-line chemotherapy and secondary cytoreductive surgery (CRS). RESULTS: 138 patients were included. The BEV (n = 36) and non-BEV (n = 102) groups had similar initial FIGO stages and proportions of secondary CRS. The BEV group showed improved progression-free survival (PFS; median, 15.4 vs. 7.5 months; P = 0.042) and overall survival (OS; P = 0.043) compared to the non-BEV group. In multivariate analyses, BEV was identified as an independent prognostic factor for PFS (adjusted hazard ratio [aHR], 0.571; 95% confidence interval [CI], 0.354-0.921; P = 0.022) and OS (aHR, 0.435; 95%CI, 0.195-0.970; P = 0.042). The secondary CRS group (n = 42) had early-stage disease at diagnosis more frequently (P = 0.009) and multi-site metastasis (P < 0.001) at recurrence less frequently than the no surgery group (n = 96). The secondary CRS group showed significantly better PFS (median, 33.7 vs. 7.2 months; P < 0.001) and OS (P < 0.001). Secondary CRS was associated with a significantly improved PFS (aHR, 0.297; 95% CI, 0.183-0.481; P < 0.001) and OS (aHR, 0.276; 95% CI, 0.133-0.576; P = 0.001). The BEV and non-BEV groups showed similar PFS and OS among the patients who underwent secondary CRS. In contrast, the BEV group showed improved PFS and OS among patients who did not undergo surgery. CONCLUSIONS: The use of BEV during second-line chemotherapy and secondary CRS may improve PFS and OS in patients with platinum-sensitive relapsed OCCC. Further prospective studies are warranted.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Kim SI, Kim JH, Noh JJ, et al. Impact of bevacizumab and secondary cytoreductive surgery on survival outcomes in platinum-sensitive relapsed ovarian clear cell carcinoma: A multicenter study in Korea. Gynecol Oncol. 2022. PMID: 35863991. doi:10.1016/j.ygyno.2022.07.011

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。